Predictive factors of radioiodine ablation success: results from a MEDIRAD prospective clinical study for thyroid cancer
Authors' conclusion
Predictions of ablation success using post-operative stimulated thyroglobulin or the absorbed dose to the thyroid remnant could inform personalisation of management of differentiated thyroid cancer and identify patients where further treatments or more intensive follow-up are required. Patients with a post-operative stimulated Tg of <1 ng/mL likely do not benefit from radioiodine.
Study context
- Population
- DTC patients treated with 1.1 or 3.7 GBq radioiodine after rhTSH stimulation or thyroid hormone withdrawal, France, Germany and UK; with follow-up data and negative antithyroglobulin antibody testsnegative TgAb, with follow-up
- Participants
- 94 patients
- Exposure
- Post-operative stimulated Tg vs maximum absorbed dose to thyroid remnant for predicting ablation success
- Outcome
- Ablation success: unstimulated or stimulated Tg <0.2 or <1.0 ng/mL
- Follow-up
- 9-12 months post-radioiodine
Methodological detailsmulticentre, multinational (France, Germany, UK), aligned study endpoints (MEDIRAD)
- Multicentre
- Multinational (France, Germany, UK)
- Aligned study endpoints (MEDIRAD)
Main finding
As reported in the abstract
Prediction of ablation success (ROC AUC)
| Group | AUC | P |
|---|---|---|
| Post-operative stimulated Tg | 0.83 ± 0.05 | P < 0.001 |
| Maximum absorbed dose | 0.64 ± 0.08 | P = 0.12 |
AUC
Post-operative stimulated Tg0.83 ± 0.05
Maximum absorbed dose0.64 ± 0.08
P
Post-operative stimulated TgP < 0.001
Maximum absorbed doseP = 0.12
Observational data: associations, not effects.
Further findings
Excellent biochemical response · 9-12 months post-radioiodine
- Excellent biochemical responders
- 78 (83%)
Dose-response between maximum absorbed dose and ablation success
- Dose-response relationship found in patients with post-operative stimulated Tg ≥1 ng/mL
Original publication
Predictive factors of radioiodine ablation success: results from a MEDIRAD prospective clinical study for thyroid cancer. Eur Thyroid J. Published 18 June 2025. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →